Table 3 Diagnostic accuracy of tumour markers in patients with negative cytology
From: Evaluation of two strategies for the interpretation of tumour markers in pleural effusions
Single cut-offa | Ratio F/Sb | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Sensitivity | NPV | Specificity | PPV | Accuracy | Sensitivity | NPV | Specificity | PPV | Accuracy | |
CEA | 32.9 | 85.4 | 100.0 | 100.0 | 86.3 | 48.6 | 88.5 | 99.0 | 94.4 | 89.1 |
CA15-3 | 24.3 | 83.9 | 100.0 | 100.0 | 84.7 | 30.0 | 84.9 | 98.6 | 84.0 | 84.8 |
CA72-4 | 25.0 | 84.0 | 100.0 | 100.0 | 83.5 | 28.6 | 84.8 | 100.0 | 100.0 | 85.1 |
CA19-9 | 20.3 | 82.8 | 100.0 | 100.0 | 84.8 | 25.7 | 84.2 | 100.0 | 100.0 | 85.7 |
All TM | 51.4 | 89.1 | 100.0 | 100.0 | 90.3 | 71.4 | 93.2 | 98.2 | 90.9 | 92.8 |
Effusions with ADA < 45U/L; CRP < 50 mg/L and %polymorphonuclear cells <90 | ||||||||||
CEA | 40.0 | 85.8 | 100.0 | 100.0 | 87.1 | 58.2 | 89.8 | 100.0 | 100.0 | 91.1 |
CA15-3 | 21.8 | 82.5 | 100.0 | 100.0 | 83.3 | 27.3 | 83,5 | 100.0 | 100.0 | 84.5 |
CA72-4 | 27.3 | 82.9 | 100.0 | 100.0 | 83.3 | 30.9 | 84.2 | 100.0 | 100.0 | 84.4 |
CA19-9 | 24.1 | 82.4 | 100.0 | 100.0 | 83.9 | 27.3 | 83.5 | 100.0 | 100.0 | 85.3 |
All TM | 54.5 | 89.0 | 100.0 | 100.0 | 90.3 | 72.7 | 93.1 | 100.0 | 100.0 | 94.2 |
Effusions with ADA > 45U/L; CRP > 50 mg/L and/or %polymorphonuclear cells >90 | ||||||||||
CEA | 10.5 | 81.5 | 100.0 | 100.0 | 84.3 | 13.3 | 85.1 | 97.4 | 50.0 | 83.5 |
CA15-3 | 31.6 | 85.1 | 100.0 | 100.0 | 88.8 | 40.0 | 88.9 | 94.7 | 60.0 | 85.7 |
CA72-4 | 18.8 | 82.2 | 100.0 | 100.0 | 83.9 | 20.0 | 86.4 | 100.0 | 100.0 | 86.8 |
CA19-9 | 10.5 | 81.5 | 100.0 | 100.0 | 87.2 | 20.0 | 86.4 | 100.0 | 100.0 | 86.8 |
All TM | 40.0 | 86.5 | 100.0 | 100.0 | 90.1 | 66.7 | 93.4 | 93.4 | 66.7 | 89.0 |